Inspira Technologies Oxy B.H.N. Ltd Ordinary Shares IINN 深 沪
等待开盘 11-06 09:30:00 美东时间
0.9081
+0.029
+3.25%
华盛通- 最 高0.92
- 今 开0.8726
- 成交量 14.12万股
- 最 低 0.8726
- 昨 收 0.8795
- 总市值 2326.49万
- 52周最高 1.65
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 0.4026
- 委 比 78.53%
- 总股本 2561.93万
- 历史最高 9.59
- 量 比 0.60
- 振 幅 5.39%
- 历史最低 0.4026
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira’s Global Ecosystem
Inspira Technologies has entered into a strategic collaboration with Bites Learning to integrate Bites' AI-powered learning platform into Inspira's medical devices, enhancing training and operational efficiency for global customers. This partnership aims to simplify onboarding, reduce support burdens, and create a competitive edge for Inspira.
10-22 12:30
Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira Technologies has appointed Mike Hershkovitz as Vice President of Global Sales and Sivan Matza to its Board of Directors. Hershkovitz brings over 20 years of experience in healthcare sales, while Matza, an expert in global finance, joins as an independent director. These appointments aim to enhance the Company's commercial expansion and governance.
10-21 13:05
Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update
Inspira Technologies reported strong progress in the first half of 2025, securing $49.5 million in binding purchase orders and achieving 97.35% accuracy for its HYLA blood sensor. The company expanded clinical use of its ART100 system in leading hospitals and received U.S. patent protection for its core technology. Despite increased operating expenses, Inspira anticipates revenue recognition from these orders starting in 2026 and targeting an ann...
10-01 12:00
Inspira to Unveil HYLA™ Real-Time Blood Sensor at U.S. ELSO; 97.35% Accuracy Confirmed
<p>Inspira Technologies will showcase its HYLA blood sensor at the U.S. ELSO Annual Conference, highlighting its 97.35% accuracy compared to standard blood gas analyzers. The event serves as a platform to engage with global clinicians and advance commercialization discussions. The company will also demonstrate its FDA-cleared ART100 system, underscoring its commitment to innovative life-support solutions.</p>
09-18 12:00
Inspira Technologies Reports Pivotal Results For HYLA Blood Sensor, Achieving 97.35% Accuracy In Latest Performance Testing Phase That Will Support Upcoming FDA Submission
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced pivotal results for its
09-11 21:32
Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance
Inspira Technologies announced that its HYLA blood sensor achieved 97.35% accuracy in performance testing, supporting upcoming FDA submission. The device features continuous, non-invasive monitoring and is versatile for various medical procedures. HYLA is designed to integrate with existing devices, targeting global markets with a recurring revenue model. The Company highlighted its potential to revolutionize real-time blood monitoring in critica...
09-11 13:30
Inspira Technologies Says A U.S. Hospital Expands Clinical Use Of INSPIRA ART100 System To Lung Transplantation Procedures
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that a top U.S.
09-02 21:07
Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market
<p>Israel-based Inspira Technologies has received U.S. Patent approval for its low-flow extracorporeal oxygenation system, a key technology for its ART500 device targeting a $20 billion respiratory support market. The patent, valid until 2043, strengthens the company's intellectual property and positions it for growth in underserved patient populations. CEO Dagi Ben-Noon emphasized the patent's strategic importance in advancingInspira's leadershi...
08-22 12:45
Inspira Technologies Says National Ministry Of Health In Africa Places $27M Binding Purchase Order For Inspira's FDA-Cleared ART100 Systems
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that a national ministry
08-19 20:40
Inspira Clarifies Routine Nature of Registration Statement on Form F-3 Filing Performed Every Three Years
Inspira Technologies OXY B.H.N. Ltd. has filed a new shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission (SEC) as part of its routine three-year renewal process. The updated filing replaces the Company's previous shelf registration statement, which is set to expire on August 18, 2025. Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, including the FDA-c...
08-07 13:44
